Quick Answer
IONIS PHARMACEUTICALS INC reported Research And Development Expense of $915.62 million for the year ending 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +1.6% in Research And Development Expense from 2024 to 2025.
- This data is from IONIS PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2009: $32.15 million | Q3 2009: $33.83 million | Q1 2010: $31.99 million | Q2 2010: $39.12 million | Q3 2010: $34.72 million | Q1 2011: $34.25 million | Q2 2011: $36.01 million | Q3 2011: $39.92 million | Q1 2012: $38.71 million | Q2 2012: $40.44 million | Q3 2012: $36.55 million | Q1 2013: $38.31 million | Q2 2013: $42.63 million.
- Over the full 8 years of available data (2008 to 2025), IONIS PHARMACEUTICALS INC's Research And Development Expense has grown by 760.2%.
- Historical annual values: Fiscal year 2025: $915.62 million | Fiscal year 2024: $901.53 million | Fiscal year 2023: $899.63 million | Fiscal year 2012: $158.46 million | Fiscal year 2011: $157.40 million | Fiscal year 2010: $145.16 million | Fiscal year 2009: $134.62 million | Fiscal year 2008: $106.44 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: